FVFIGP
MCRB icon

Flagship Ventures Fund IV General Partner’s Seres Therapeutics MCRB Stock Holding History

Flagship Ventures Fund IV General Partner’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$368M Buy
+634,144
New +$372M 62.99% 1
2015
Q4 		$494M Buy
+704,179
New +$463M 97.53% 1

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Flagship Ventures Fund IV General Partner's MCRB Position: Q2 2016 in Review

Flagship Ventures Fund IV General Partner opened a new position in Seres Therapeutics (MCRB) in Q2 2016: 634,144 shares worth $368M. The stake represents 62.99% of the portfolio and ranks #1 among its holdings. This is a return to the name: Flagship Ventures Fund IV General Partner previously reported a position in MCRB as recently as Q4 2015.

Flagship Ventures Fund IV General Partner first reported a position in MCRB in Q4 2015 and has held it in 2 quarters since. The position peaked at $494M in Q4 2015. 91 funds tracked by Wall St. Rank hold MCRB as of Q2 2016.

  • Flagship Ventures Fund IV General Partner held 634,144 shares of Seres Therapeutics worth $368M as of Q2 2016.
  • Seres Therapeutics was a new Flagship Ventures Fund IV General Partner position in Q2 2016.
  • Seres Therapeutics made up 62.99% of Flagship Ventures Fund IV General Partner's portfolio in Q2 2016, its #1 holding.
  • Flagship Ventures Fund IV General Partner first reported a position in Seres Therapeutics in Q4 2015 and has held it in 2 quarters since.
  • Flagship Ventures Fund IV General Partner's Seres Therapeutics position peaked at $494M in Q4 2015.
  • 91 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2016.

Based on Flagship Ventures Fund IV General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.